Jeffrey M. Leiden, Executive Chairman of Vertex Pharmaceuticals (VRTX) and OcuDyne (ODTX), has filed 51 Form 4 transactions across the two companies, with a pronounced selling bias. His open-market sales in VRTX totaled roughly $68.9 million, dominated by a cluster of 11 sales on December 3, 2025, ranging from $515,001 to $7.09 million per transaction. Those sales, executed in a single day, reflect a systematic liquidation of a large position rather than a staggered exit. In contrast, his only open-market purchase was a $100,000 buy of ODTX shares on May 8, 2026, a modest sum relative to his VRTX sales and the sole "P" code in his recent activity.
The ODTX activity is largely mechanical: on May 11, 2026, Leiden exercised options (code M), converted derivatives (code C), and had 306 shares withheld for taxes (code F), all valued at zero except the nominal tax withholding. A May 7 grant (code A) added shares without cash outlay. This pattern—compensation-driven accumulation in ODTX with a token purchase—contrasts sharply with the VRTX sales, which were outright dispositions. His VRTX activity also included routine tax withholdings (codes F) on February 18 and 24, 2026, totaling $3.15 million, alongside grants (code A) in January and February.
The data shows no recent selling in ODTX and no buying in VRTX, suggesting Leiden is monetizing his VRTX stake while building a small, mostly non-cash position in ODTX. The December 2025 VRTX sales, executed across 11 separate filings, represent the bulk of his realized value—over $68 million—and were not offset by any contemporaneous purchases. His only cash buy, the $100,000 ODTX purchase, is a rounding error against that total, underscoring a clear directional tilt toward distribution rather than accumulation.
AI-assisted summary